Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 CXCR4-based imaging agents.

Literature DB >> 22045705

CXCR4-based imaging agents.

Abstract

Chemokine receptor 4 (CXCR4)-chemokine ligand 12 (CXCL12) interactions have been shown to play key roles in cancer cell survival, proliferation, chemotaxis, homing, adhesion, tumor angiogenesis, and resistance to conventional and targeted therapies. Given its extensive involvement in cancer progression, the CXCR4-CXCL12 axis has been considered a therapeutic target. Several inhibitors blocking this signaling cascade are in phase I trials. Because CXCR4 is constitutively expressed in a wide variety of normal tissues, patient stratification and noninvasive monitoring would improve therapeutic outcome and reduce unnecessary toxicities. This review focuses on recent developments in CXCR4-based imaging agents and their potential role in the molecular diagnosis and treatment of cancer.

Entities: CellLine Chemical Disease Gene Species

Mesh：

Substances：

Year: 2011 PMID： 22045705 PMCID： PMC3715079 DOI： 10.2967/jnumed.111.097733

Source DB: PubMed Journal: J Nucl Med ISSN： 0161-5505 Impact factor: 10.057

38 in total

Review 1. Chemokines and their receptors: drug targets in immunity and inflammation.

Authors: Antonella Viola; Andrew D Luster
Journal: Annu Rev Pharmacol Toxicol Date: 2008 Impact factor: 13.820

2. The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study.

Authors: Ombretta Salvucci; Amélie Bouchard; Andrea Baccarelli; Jean Deschênes; Guido Sauter; Ronald Simon; Rosella Bianchi; Mark Basik
Journal: Breast Cancer Res Treat Date: 2005-12-13 Impact factor: 4.872

Review 3. Development of low molecular weight CXCR4 antagonists by exploratory structural tuning of cyclic tetra- and pentapeptide-scaffolds towards the treatment of HIV infection, cancer metastasis and rheumatoid arthritis.

Authors: Hirokazu Tamamura; Hiroshi Tsutsumi; Hiroyuki Masuno; Nobutaka Fujii
Journal: Curr Med Chem Date: 2007 Impact factor: 4.530

4. 64Cu-AMD3100--a novel imaging agent for targeting chemokine receptor CXCR4.

Authors: Orit Jacobson; Ido D Weiss; Lawrence Szajek; Joshua M Farber; Dale O Kiesewetter
Journal: Bioorg Med Chem Date: 2009-01-15 Impact factor: 3.641

5. Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects.

Authors: Nimalie D Stone; Shelia B Dunaway; Charles Flexner; Camlin Tierney; Gary B Calandra; Stephen Becker; Ying-Jun Cao; Ilene P Wiggins; Jeanne Conley; Ron T MacFarland; Jeong-Gun Park; Christina Lalama; Sally Snyder; Beatrice Kallungal; Karin L Klingman; Craig W Hendrix
Journal: Antimicrob Agents Chemother Date: 2007-04-23 Impact factor: 5.191

6. CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature.

Authors: Zhenhua Miao; Kathryn E Luker; Bretton C Summers; Rob Berahovich; Mahaveer S Bhojani; Alnawaz Rehemtulla; Celina G Kleer; Jeffrey J Essner; Aidas Nasevicius; Gary D Luker; Maureen C Howard; Thomas J Schall
Journal: Proc Natl Acad Sci U S A Date: 2007-09-26 Impact factor: 11.205

7. CXCL12/CXCR4 transactivates HER2 in lipid rafts of prostate cancer cells and promotes growth of metastatic deposits in bone.

Authors: Sreenivasa R Chinni; Hamilto Yamamoto; Zhong Dong; Aaron Sabbota; R Daniel Bonfil; Michael L Cher
Journal: Mol Cancer Res Date: 2008-03 Impact factor: 5.852

Review 8. Targeting the CXCR4/CXCL12 axis in systemic lupus erythematosus.

Authors: Benjamin F Chong; Chandra Mohan
Journal: Expert Opin Ther Targets Date: 2009-10 Impact factor: 6.902

9. Immunoimaging of CXCR4 expression in brain tumor xenografts using SPECT/CT.

Authors: Sridhar Nimmagadda; Mrudula Pullambhatla; Martin G Pomper
Journal: J Nucl Med Date: 2009-06-12 Impact factor: 10.057

10. PET imaging of CXCR4 using copper-64 labeled peptide antagonist.

Authors: Orit Jacobson; Ido D Weiss; Lawrence P Szajek; Gang Niu; Ying Ma; Dale O Kiesewetter; Joshua M Farber; Xiaoyuan Chen
Journal: Theranostics Date: 2011-04-19 Impact factor: 11.556

18 in total

1. In vivo Evaluation of an Engineered Cyclotide as Specific CXCR4 Imaging Reagent.

Authors: Wojciech G Lesniak; Teshome Aboye; Samit Chatterjee; Julio A Camarero; Sridhar Nimmagadda
Journal: Chemistry Date: 2017-08-03 Impact factor: 5.236

2. A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4.

Authors: Geert Schoofs; Anneleen Van Hout; Thomas D'huys; Dominique Schols; Tom Van Loy
Journal: J Vis Exp Date: 2018-03-10 Impact factor: 1.355

Review 10. Small molecule inhibitors of CXCR4.

Authors: Bikash Debnath; Shili Xu; Fedora Grande; Antonio Garofalo; Nouri Neamati
Journal: Theranostics Date: 2013-01-15 Impact factor: 11.556

CXCR4-based imaging agents.

Review 1. Chemokines and their receptors: drug targets in immunity and inflammation.

2. The role of CXCR4 receptor expression in breast cancer: a large tissue microarray study.

Review 3. Development of low molecular weight CXCR4 antagonists by exploratory structural tuning of cyclic tetra- and pentapeptide-scaffolds towards the treatment of HIV infection, cancer metastasis and rheumatoid arthritis.

4. 64Cu-AMD3100--a novel imaging agent for targeting chemokine receptor CXCR4.

5. Multiple-dose escalation study of the safety, pharmacokinetics, and biologic activity of oral AMD070, a selective CXCR4 receptor inhibitor, in human subjects.

6. CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature.

7. CXCL12/CXCR4 transactivates HER2 in lipid rafts of prostate cancer cells and promotes growth of metastatic deposits in bone.

Review 8. Targeting the CXCR4/CXCL12 axis in systemic lupus erythematosus.

9. Immunoimaging of CXCR4 expression in brain tumor xenografts using SPECT/CT.

10. PET imaging of CXCR4 using copper-64 labeled peptide antagonist.

1. In vivo Evaluation of an Engineered Cyclotide as Specific CXCR4 Imaging Reagent.

2. A Flow Cytometry-based Assay to Identify Compounds That Disrupt Binding of Fluorescently-labeled CXC Chemokine Ligand 12 to CXC Chemokine Receptor 4.

3. Symmetrical bis-tertiary amines as novel CXCR4 inhibitors.

Review 4. Radiotheranostics in Cancer Diagnosis and Management.

5. Structural characterization and in vivo evaluation of β-Hairpin peptidomimetics as specific CXCR4 imaging agents.

Review 6. Molecular imaging to guide systemic cancer therapy: Illustrative examples of PET imaging cancer biomarkers.

7. High expression of SDF-1 and VEGF is associated with poor prognosis in patients with synovial sarcomas.

Review 8. In vivo imaging of therapy-induced anti-cancer immune responses in humans.

9. Differential Expression of Chemokine Receptors and their Roles in Cancer Imaging.

Review 10. Small molecule inhibitors of CXCR4.